Therapeutic | Rozipafusp |
Target | ICOS |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK |
100% seqID Fv Structure | 6x4t [Fvs: BE, DF] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6x4t [Fvs: BE, DF] |
Follow these links to our prediction tools:
Format | Whole mAb Fusion |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-I |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | None |
Companies Involved | Amgen |
Conditions Approved | na |
Conditions Active | Rheumatoid arthritis |
Conditions Discontinued | Systemic lupus erythematosus |
Notes |